Jan 4 |
BriaCell Images Confirm Robust Anti-Tumor Activity in Patient with “Eye-Bulging” Metastatic Breast Cancer
|
Dec 28 |
BriaCell Reports 71% Central Nervous System Response Rate in Advanced Breast Cancer Patients
|
Dec 20 |
BriaCell Reports Unprecedented Preliminary Survival and Clinical Benefit in Antibody-Drug Conjugate (ADC) Refractory Patient Subset
|
Dec 18 |
BCTX: Down in San Antone
|
Dec 6 |
BriaCell Highlights Outstanding Topline Survival and Clinical Benefit Data in Advanced Metastatic Breast Cancer at the 2023 SABCS
|
Dec 6 |
BriaCell 2023 SABCS Posters Confirm Activation of Cancer-Fighting Immune Cells and Identify Potential Predictors of Clinical Benefit
|
Dec 1 |
Here's Why We're Watching BriaCell Therapeutics' (TSE:BCT) Cash Burn Situation
|
Nov 30 |
BriaCell Records New Responder with Remarkable Improvement of “Eye-Bulging” Metastatic Tumor
|
Nov 8 |
BCTX: November 2023 SITC Poster
|
Nov 3 |
BriaCell Reports Unprecedented Anti-Tumor Activity of its Next Generation Personalized Breast and Prostate Cancer Immunotherapies in Tumor Models at the 2023 SITC Annual Meeting; FDA Greenlights Bria-OTS™ IND
|